Tazemetostat Hydrobromide
Sponsors
National Cancer Institute (NCI)
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8Extensive Stage Lung Small Cell CarcinomaLimited Stage Lung Small Cell CarcinomaMetastatic MelanomaPlatinum-Resistant Lung Small Cell CarcinomaPlatinum-Sensitive Lung Small Cell CarcinomaRecurrent Extensive Stage Lung Small Cell CarcinomaRecurrent Lung Small Cell Carcinoma
Phase 1
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment
Active, not recruitingNCT04557956
Start: 2021-08-19End: 2027-03-11Updated: 2026-04-02
Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer
Active, not recruitingNCT05353439
Start: 2022-07-27End: 2027-03-13Updated: 2026-04-03